por Sean Ruck
, Contributing Editor | December 28, 2015
From the December 2015 issue of HealthCare Business News magazine
To provide patients with a one-stop destination for all of their medical records, Medfusion — a patient engagement platform dedicated to facilitating the relationship between doctors and patients — has developed a consumer mobile application — Medfusion Plus.
Via a download on the App Store and Google Play, iOS and Android device users can now aggregate and access their healthcare records onto their mobile devices. The information is pulled via Continuity of Care documents (CCD) from the patient portals and includes laboratory results, immunizations, medication lists, allergies, as well as appointments.
Quest Imaging Solutions provides all major brands of surgical c-arms (new and refurbished) and carries a large inventory for purchase or rent. With over 20 years in the medical equipment business we can help you fulfill your equipment needs
Medfusion Plus, which also provides an application programming interface and is available on the Apple Watch, will continue to evolve with a significant roadmap ahead for the developers.
Diagnostic Suite for IQon Spectral CT
Diagnostic Suite for
IQon Spectral CT
Royal Philips announced that its IQon Spectral CT now has increased potential thanks to a new diagnostic suite approved for the U.S. market.
By providing spectral capabilities within traditional CT applications, the Spectral Diagnostic Suite may unlock a new level of flexibility and clinical utility for the workhorse imaging modality. It may also reduce repeat imaging, as incidental findings can be explored in greater depth with the spectral data sets.
The visual and analytical benefits of the Spectral Diagnostic Suite can be tapped into from a variety of different settings. According to a statement from Philips, the spectral data can be viewed from a reading room, a PACS system, or a remote location.
The IQon Spectral CT system itself received FDA approval in November of 2014.
High Intensity Focused Ultrasound Prostate Ablation Device
High Intensity Focused
SonaCare Medical, LLC announced that it received de novo clearance from the U.S. Food and Drug Administration (FDA) to market the Sonablate® 450 in the U.S. for the ablation of prostate tissue. Sonablate® is the first High Intensity Therapeutic Ultrasound (HITU) device to receive FDA regulatory authorization for prostate tissue ablation.